Published in Vaccine Weekly, June 15th, 2005
The bridging study is designed to compare the immune response and safety of the StaphVAX material produced by the company's contract manufacturer with that of the StaphVAX lot from the company's phase III clinical trial in end-stage renal disease (ESRD) patients. The consistency lot study is being conducted in healthy adults to compare the safety and immunogenicity of three commercial lots of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly